Comprehensive Surgical Treatment as the Mainstay of Management in Retroperitoneal Sarcomas: Retrospective Study from Two Non-sarcoma Specialist Centers.

Published

Journal Article

Complete resection, surgical expertise and individualization of patient management in comprehensive oncology centres result in better clinical outcomes in patients presenting with retroperitoneal sarcomas.Clinical outcomes of primary and recurrent retroperitoneal sarcoma resections performed between January 2002 and December 2016 in two large surgical oncology, but non-sarcoma specialist centers, were reviewed to determine the efficacy of complete surgical resection as the principle instrument for treatment. The histological type, tumor size and grade, as well as organ resection, were recorded and subsequently reviewed.Our study included 108 cases of sarcoma resection (60 first-time, 38 second-time and 10 third-time laparotomies) in 60 patients (35 males and 25 females). Most patients had complete resection: 57 had a macroscopically complete (R0/R1) resection and three had R2 resection. The 90-day mortality rate was zero and morbidity was minimal. Five- and 10-year overall survival (OS) rates were 88% and 79%, respectively, whereas the corresponding disease-free survival (DFS) rates were 65% and 59%, respectively. High-grade tumors were associated with decreased DFS (hazard ratio(HR)=3.35; 95% confidence interval(CI)=1.23-9.10; p=0.018) and decreased OS (HR=7.18; 95% CI=1.50-34.22; p=0.013).Complete surgical resection of retroperitoneal sarcomas combined with individualized patient management when offered by experienced surgical oncology teams, adhering to international guidelines, can succeed in providing patients with good long-term outcomes, comparable to those achieved at sarcoma-specialist centers.

Full Text

Duke Authors

Cited Authors

  • Petrou, A; Constantinidou, A; Kontos, M; Papalampros, A; Moris, D; Bakoyiannis, C; Neofytou, K; Kourounis, G; Felekouras, E

Published Date

  • April 2017

Published In

Volume / Issue

  • 37 / 4

Start / End Page

  • 2025 - 2031

PubMed ID

  • 28373477

Pubmed Central ID

  • 28373477

Electronic International Standard Serial Number (EISSN)

  • 1791-7530

International Standard Serial Number (ISSN)

  • 0250-7005

Digital Object Identifier (DOI)

  • 10.21873/anticanres.11547

Language

  • eng